Anil Shankar Quoted on Pharma Decision, Impact on 340B Drug Pricing

Foley & Lardner LLP partner Anil Shankar offered insight on a recent decision which held that the federal 340B drug pricing program does not bar pharmaceutical drug manufacturers from imposing contractual conditions on contract pharmacies in the Law360 article, “DC Circ. Decision May Lead To Tighter 340B Pharma Contracts.”

Shankar explained that the decision made it clear to manufacturers that they could impose restrictions.

“It will make it easier for manufacturers to impose restrictions as long as they’re reasonable and consistent with the 340B statute,” he added.

(Subscription required)